ARUP LABORATORIES

A nonprofit enterprise of the University of Utah and its Department of Pathology

Hotline Table of Contents

Effective as of 06/03/2024

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Information regarding Current Procedural Terminology (CPT)

Test Number	Mnemonic	Test Name	New Test	Test Name Change	Specimen Requirements	Methodology	Performed/Reported	Note	Interpretive Data	Reference Interval	Component Charting Name	Component Change	Reflex Pattern	Result Type	Ask at Order Prompt	Numeric Map	Unit of Measure	CPT Code	Pricing Change	Inactivation w/ Replacement	Inactivation w/o Replacement
0095044	PRENATAL A	Prenatal Reflexive Panel (Inactive as of 6/3/24)																			x
3017043	ADA PAN	Adalimumab and Antibodies to Adalimumab Quantitation			x																

TEST CHANGE

Adalimumab and Antibodies to Adalimumab Quantitation

3017043, ADA PAN

Specimen Requirements:	
Patient Preparation:	Collect specimens before next scheduled dose of adalimumab or adalimumab biosimilar (trough specimen). Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.
Collect:	Serum separator tube.
Specimen Preparation:	Separate serum from cells ASAP. Transfer 1 mL serum to an ARUP standard transport tube. (Min 0.1 mL) New York State Clients: 2 mL (Min: 1 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Grossly hemolyzed, icteric, or lipemic specimens.
Remarks:	
Stability:	After separation from cells: Ambient: 2 days; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles). New York State Clients: Ambient: 1 week; Refrigerated: 1 week; Frozen: 308 days
Methodology:	Quantitative Electrochemiluminescent Immunoassay (ECLIA) with Acid Dissociation
Performed:	Sun-Sat
Reported:	3-7 days
Note:	
CPT Codes:	80145; 82397
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Interpretive Data:

Adalimumab Quantitation:

Results of 0.4 ug/mL or higher indicate the detection of adalimumab or an adalimumab biosimilar. Therapeutic level may vary depending on the disease being treated.

Antibodies to Adalimumab Quantitation:

Results of 20 ng/mL or higher indicate the detection of antibodies against adalimumab or an adalimumab biosimilar. Interpret in the context of adalimumab or adalimumab biosimilar trough concentration to determine clinical significance and impact on treatment efficacy.

Reference Interval:

Test Number	Components	Reference Interval
	Adalimumab Quantitation	0.4 ug/mL or greater
	Antibodies to Adalimumab Quantitation	19 ng/mL or less

ARUP LABORATORIES

A nonprofit enterprise of the University of Utah and its Department of Pathology

Inactivations

The following will be discontinued from ARUP's test menu on June 3, 2024
Replacement test options are indicated when applicable.

Test Number	Test Name	Refer to Replacement Test
0095044	Prenatal Reflexive Panel (Inactive as of 6/3/24)	